Results 31 to 40 of about 57,449 (202)

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach

Addiction Science & Clinical Practice, 2020
Background The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction. Case presentation We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk ...
Jennifer Rozylo, Keren Mitchell, Mohammadali Nikoo, S. Elise Durante, Skye P. Barbic, Daniel Lin, Steve Mathias, Pouya Azar   +7 more
doaj   +1 more source

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder - a case report

European Psychiatry
Introduction Opioid dependence is a complex condition that often requires long-term treatment and care. Methadone, a synthetic full opioid agonist, and buprenorphine, a partial agonist at the opioid receptor, are most commonly used for substitution ...
M. Delic
doaj   +1 more source

Improving Uptake of Emergency Department-initiated Buprenorphine: Barriers and Solutions

Western Journal of Emergency Medicine, 2022
Emergency departments (ED) are increasingly providing buprenorphine to persons with opioid use disorder. Buprenorphine programs in the ED have strong support from public health leaders and emergency medicine specialty societies and have proven to be ...
Timothy D. Kelly, Kathryn F. Hawk, Elizabeth A. Samuels, Reuben J. Strayer, Jason A. Hoppe   +4 more
doaj   +1 more source

Low-dose buprenorphine initiation during pregnancy: a case report

AJOG Global Reports
Buprenorphine is recommended for pregnant patients with opioid use disorder. Traditional buprenorphine initiation requires moderate withdrawal symptoms to prevent precipitating withdrawal.
Shivania Reddy, BSc, Caitlin E. Martin, MD, MPH, FACOG, FASAM   +1 more
doaj   +1 more source

Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study

Annals of Medicine, 2023
Background: At the start of the pandemic, relaxation of buprenorphine prescribing regulations created an opportunity to create new models of medications for opioid use disorder (MOUD) delivery and care.
Edward Suarez, Tyler S. Bartholomew, Marina Plesons, Katrina Ciraldo, Lily Ostrer, David P. Serota, Teresa A. Chueng, Morgan Frederick, Jason Onugha, Hansel E. Tookes   +9 more
doaj   +1 more source

Buprenorphine [PDF]

Journal of Pain and Symptom Management, 2013
Bethany, Foster, Robert, Twycross, Mary, Mihalyo, Andrew, Wilcock   +3 more
  +5 more sources

Patient experiences of buprenorphine dispensing from a mobile medical unit

Addiction Science & Clinical Practice
Background Overdose deaths continue to rise within the United States, despite effective treatments such as buprenorphine and methadone for opioid use disorder (OUD).
Sarah E. Messmer, Abigail T. Elmes, Alexander F. Infante, Anna Patterson, Mackenzie Smith, Albert Leon Murphy, Antonio D. Jimenez, Stockton Mayer, Dennis P. Watson, Kevin Whitfield, Steven J. Fisher, Jennie B. Jarrett   +11 more
doaj   +1 more source

A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder

Drugs in R&D, 2023
Buprenorphine has become an important medication in the context of the ongoing opioid epidemic. However, complex pharmacologic properties and varying government regulations create barriers to its use.
James C. Miller, Michael A. Brooks, Kelly E. Wurzel, Emily J. Cox, John F. Wurzel   +4 more
doaj   +1 more source

Transdermal Buprenorphine Use for Pain Management in Palliative Care [PDF]

, 2021
Jessica Hirsch, Sachin Kale, Marilly Palettas, Justin Kullgren   +3 more
openalex   +1 more source

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes

Substance Abuse: Research and Treatment, 2013
Given that buprenorphine + naloxone is prescribed for opioid-dependent pregnant women, it is important to examine the extent to which it differs from buprenorphine alone, methadone, or methadone-assisted withdrawal on neonatal and maternal outcomes ...
Ingunn O. Lund, Gabriele Fischer, Gabrielle K. Welle-Strand, Kevin E. O'grady, Kimber Debelak, William R. Morrone, Hendrέe E. Jones   +6 more
doaj   +1 more source